BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of EUR 23.31 billion. The enterprise value is 9.50 billion.

Market Cap	23.31B
Enterprise Value	9.50B

Important Dates

The last earnings date was Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.29%
Shares Change (QoQ)	+0.53%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.10
PB Ratio	1.26
P/TBV Ratio	1.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-27.55
EV / Sales	3.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.87

Financial Position

The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.01.

Current Ratio	8.61
Quick Ratio	8.37
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.14
Interest Coverage	-42.71

Financial Efficiency

Return on equity (ROE) is -1.84% and return on invested capital (ROIC) is -2.47%.

Return on Equity (ROE)	-1.84%
Return on Assets (ROA)	-2.14%
Return on Invested Capital (ROIC)	-2.47%
Return on Capital Employed (ROCE)	-3.80%
Revenue Per Employee	425,044
Profits Per Employee	-50,916
Employee Count	6,772
Asset Turnover	0.13
Inventory Turnover	2.04

Taxes

Income Tax	-43.40M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +28.25% in the last 52 weeks. The beta is 1.24, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.24
52-Week Price Change	+28.25%
50-Day Moving Average	94.26
200-Day Moving Average	99.40
Relative Strength Index (RSI)	53.62
Average Volume (20 Days)	1,049

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.08

Income Statement

In the last 12 months, BioNTech SE had revenue of EUR 2.88 billion and -344.80 million in losses. Loss per share was -1.44.

Revenue	2.88B
Gross Profit	2.30B
Operating Income	-751.70M
Pretax Income	-388.20M
Net Income	-344.80M
EBITDA	-493.70M
EBIT	-751.70M
Loss Per Share	-1.44

Full Income Statement

Balance Sheet

The company has 14.04 billion in cash and 269.60 million in debt, giving a net cash position of 13.77 billion.

Cash & Cash Equivalents	14.04B
Total Debt	269.60M
Net Cash	13.77B
Net Cash Per Share	n/a
Equity (Book Value)	18.51B
Book Value Per Share	76.98
Working Capital	14.08B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.74 billion and capital expenditures -215.40 million, giving a free cash flow of -1.95 billion.

Operating Cash Flow	-1.74B
Capital Expenditures	-215.40M
Free Cash Flow	-1.95B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 79.76%, with operating and profit margins of -26.12% and -11.98%.

Gross Margin	79.76%
Operating Margin	-26.12%
Pretax Margin	-13.49%
Profit Margin	-11.98%
EBITDA Margin	-17.15%
EBIT Margin	-26.12%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.29%
Shareholder Yield	n/a
Earnings Yield	-1.48%
FCF Yield	-8.37%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 6.41 and a Piotroski F-Score of 2.

Altman Z-Score	6.41
Piotroski F-Score	2